Mechanisms of MHC-I Downregulation and Role in Immunotherapy Response is a research paper published in Frontiers in Immunology (2022). On theSindex it has a DataRank of 0. It has been cited 285 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: 2P50CA098131–17, T32 CA009592
U.S. Department of Defense
Grant: BC170037
NCI NIH HHS
Grant: P50 CA098131
NCI NIH HHS
Grant: T32 CA009592
FWCI
19.03
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 1 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 2 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 2 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 1 of Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
Additional file 1 of Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
Additional file 3 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 4 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 3 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 4 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 5 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 5 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 6 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 6 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 7 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 7 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 8 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 8 of Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells
Additional file 7 of Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer
Additional file 8 of Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer